Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

Podobne zapisy

• Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
  od: Hakim, James G, i wsp.
  Wydane: (2018)
• HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa
  od: Kityo, Cissy, i wsp.
  Wydane: (2017)
• The Challenge of HIV-1 Antiretroviral Resistance in Africa in the Era of HAART
  od: Sendagire, Hakim, i wsp.
  Wydane: (2009)
• HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda
  od: Kityo, Cissy, i wsp.
  Wydane: (2016)
• The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy
  od: Hosseinipour, Mina C., i wsp.
  Wydane: (2009)